Aurobindo Pharma acquired Khandelwal Laboratories’ non-oncology branded formulations business for Rs 325 crore, boosting domestic pharmaceutical portfolio and future growth.

• Khandelwal’s non-oncology business includes 23 brands, 67 SKUs, and nine pipeline products, mainly focused on anti-infective and pain management therapies segments.
• Business reported Rs 113.53 crore revenue and Rs 28.99 crore EBITDA in FY2024-25, indicating strong profitability and operational scale strength.
• Slump-sale acquisition completed January 1, 2026, includes inventory, IP, employees, and contracts, strengthening Aurobindo’s domestic market expansion strategy, significantly long-term positioning.